D. Hlávková

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.

P. Morávek, D. Vokurková, D. Hlávková, 2007, Acta medica.

Phenotype Analysis of Tumour-infiltrating Lymphocytes and Lymphocytes in Peripheral Blood in Patients with Renal Carcinoma.

P. Morávek, D. Vokurková, D. Hlávková, 2007, Acta medica.

Monitoring of serum levels of angiogenin, ENA-78 and GRO chemokines in patients with renal cell carcinoma (RCC) in the course of the treatment.

P. Morávek, M. Podhola, D. Vokurková, 2008, Acta medica.

Determination of angiogenic factors in serum by protein array in patients with renal cell carcinoma.

P. Morávek, D. Hlávková, V. Vroblová, 2008, Folia biologica.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.